Top Performing Drug – Enbrel (June Edition)
PharmaShots
JUNE 28, 2023
In July 2002, Amgen acquired the rights to Enbrel as part of its acquisition of Immunex. Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. and Canada.
40 
Let's personalize your content